查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
全球卵泡刺激素市场 - 2023-2030年
市场调查报告书
商品编码
1290408

全球卵泡刺激素市场 - 2023-2030年

Global Follicle Stimulating Hormone Market - 2023-2030
出版日期: | 出版商: DataM Intelligence | 英文 195 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

市场概况

全球促卵泡激素市场在2022年达到19亿美元，预计到2030年将见证有利可图的增长，达到29亿美元。在预测期内（2023-2030年），全球促卵泡激素市场预计将呈现5.8%的复合增长率。不孕不育症的发病率越来越高，人们对生育治疗的认识和接受程度越来越高，以及人口老龄化的加剧，都推动了促卵泡激素市场的增长趋势。

近年来，全球促卵泡激素（FSH）市场一直在不断扩大。FSH是一种生殖激素，对调节月经周期和鼓励妇女卵巢卵泡的生长至关重要。它通常被用于生育治疗和荷尔蒙替代疗法。

全球促卵泡激素市场范围包括重组FSH、尿液FSH、不孕不育治疗、辅助生殖技术和其他组成部分，这增加了促卵泡激素市场份额的使用。全球促卵泡激素市场正在扩大，原因包括生育治疗程序的技术进步，对生育治疗的认识和接受程度的提高，以及对生殖健康的日益重视。

市场动态

老龄化人口的增加推动促卵泡激素市场的增长

全球FSH市场正受到人口老龄化的推动。个人的生育潜力随着年龄的增长而降低，导致对生育治疗的需求增加，特别是FSH治疗，以解决与年龄相关的不孕不育。对生育治疗的理解和接受程度的提高，以及推迟生育的趋势，都促进了市场的上升。

例如，根据世界卫生组织（WHO）2022年的报告，到2030年，地球上每六个人中就有一个人是60岁或以上。在这个时间跨度内，60岁及以上的世界人口比例预计将从2020年的10亿增加到14亿。总的来说，老龄人口对生育的渴望和对生育解决方案的需求推动了全球促卵泡激素市场的增长。

越来越多地采用辅助生殖技术是全球卵泡刺激素市场的主要驱动力

辅助生殖技术（ART）的使用包括各种医疗技术，旨在帮助个人实现怀孕。体外受精（IVF）是最著名的ART类型之一，其中卵子和精子在实验室环境中混合受精，然后将产生的胚胎植入子宫内。

此外，多囊卵巢综合症（PCOS）患病率的上升也导致了不孕症的增加。根据美国疾病控制和预防中心（CDC）2022年的统计数据，多囊卵巢综合症是女性不孕的一个常见原因，大约影响美国6%至12%的育龄妇女。多囊卵巢综合症的持续流行将推动对不孕症治疗的需求，从而在预测期内推动全球促卵激素市场的发展。

由于不孕不育的挑战和对辅助生殖技术的需求，个人的情绪和心理受到严重影响，将阻碍市场的发展。

不孕不育和ART的社会心理后果是广泛的，它们会对患者的自我认同感和个人机构、精神健康、性和婚姻关系、生殖效率、治疗依从性和怀孕结果产生重大影响。25%至65%的接受抗逆转录病毒疗法的妇女会经历临床压力、焦虑和负面情绪，如低自尊或内疚。因此，上述因素限制了促卵泡激素市场的发展。

COVID-19影响分析

世界上许多国家的COVID-19大流行和封锁，使各行业公司的财务健康受到影响。因此，在COVID-19公共卫生紧急情况期间，美国食品和药物管理局（FDA）发布了指导方针，其中包括帮助赞助商和研究人员的一般注意事项，确保试验参与者的安全，坚持良好的临床实践（GCP），并尽量减少试验完整性的风险。

俄乌战争影响分析

俄罗斯和乌克兰之间的冲突有可能导致供应链的中断、不确定性和不稳定，这可能会影响全球卵泡刺激素（FSH）市场。FSH产品的开发和临床试验将受到影响，这将减缓创新。市场参与者可能会寻找FSH生产的多样化和替代来源。

此外，定价和需求可能受到经济影响，包括货币波动和市场动态的修改。可能会有区域差异，离冲突较近的国家会更快地感受到影响。为了驾驭潜在的障碍并抓住FSH市场的可能性，行业利益相关者必须保持持续的观察和灵活性。

目录

第一章：方法和范围

  • 研究方法
  • 报告的研究目标和范围

第二章：定义和概述

第三章：执行摘要

  • 按类型分類的片段
  • 按应用分类的片段
  • 按终端用户分类
  • 按地区分類的片段

第四章：动态变化

  • 影响因素
    • 驱动因素
      • 老龄化人口的增加
      • 越来越多地采用辅助生殖技术
    • 限制因素
      • 生育挑战给个人带来的情感和心理负担
    • 影响分析

第五章：行业分析

  • 波特的五力分析
  • 供应链分析
  • 价格分析
  • 监管分析

第六章：COVID-19分析

  • COVID-19的分析
    • COVID-19之前的情况
    • COVID-19期间的情况
    • COVID-19之后的情况
  • 在COVID-19期间的定价动态
  • 需求-供应谱系
  • 大流行期间与市场有关的政府倡议
  • 制造商的战略倡议
  • 结语

第7章：按类型

  • 重组的FSH
  • 尿液中的FSH

第8章：按应用分类

  • 不孕不育治疗
  • 辅助生殖技术(ART)
  • 其他应用

第九章：按终端用户分类

  • 不孕不育中心
  • 医院
  • 其他

第十章：按地区划分

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 西班牙
    • 意大利
    • 欧洲其他地区
  • 南美洲
    • 巴西
    • 阿根廷
    • 南美其他地区
  • 亚太地区
    • 中国
    • 印度
    • 日本
      • 亚太其他地区
  • 中东和非洲
    • 关键区域的动态

第11章 ：竞争格局

  • 竞争格局
  • 市场定位/份额分析
  • 合併和收购分析

第十二章 ：公司简介

  • Merck Serono
    • 公司概述
    • 产品组合和说明
    • 财务概况
    • 主要发展情况
  • Creative BioMart
  • Midas Pharma GmbH
  • GenPharm
  • Trumac Healthcare
  • Livzon
  • Shanghai Techwell Biopharmaceutical Co., Ltd.
  • Merck Sharp & Dohme Corp
  • Lee Biosolutions,Inc
  • BIOGENIX INC.PVT.LTD.

第十三章 ：附录

简介目录
Product Code: PH4562

Market Overview

The Global Follicle Stimulating Hormone Market reached US$ 1.9 billion in 2022 and is projected to witness lucrative growth by reaching up to US$ 2.9 billion by 2030. The global follicle stimulating hormone market is expected to exhibit a CAGR of 5.8% during the forecast period (2023-2030). The increasing prevalence of infertility, growing awareness and acceptance of fertility treatments, and growing aging population are driving the growth of the follicle stimulating hormone market trends.

The global follicle stimulating hormone (FSH) market has been expanding continuously in recent years. FSH, a reproductive hormone, is essential in regulating the menstrual cycle and encouraging the growth of ovarian follicles in women. It is commonly utilized in fertility treatments and hormone replacement therapies.

The global follicle stimulating hormone market scope comprises components encompassing recombinant FSH, urinary FSH, infertility treatment, assisted reproductive technology and others, which has increased usage of follicle stimulating hormone market share. The global market for follicle stimulating hormones is expanding as a result of factors including technological advancements in fertility treatment procedures, increasing awareness and acceptance of fertility treatments, and increasing focus on reproductive health.

Market Dynamics

An Increase in Aging Population Drive the Growth of the Follicle Stimulating Hormone Market

The global FSH market is being driven by an aging population. Individuals' fertility potential reduces as they age, resulting in an increased demand for fertility treatments, especially FSH treatment, to address age-related infertility. The increased understanding and acceptability of fertility treatments, as well as the trend of postponed childbirth, have all contributed to the market's rise.

For instance, according to World Health Organization (WHO) 2022 report, by 2030, about one out of every six people on the planet will be 60 or older. Within this time span, the share of the world population aged 60 and up is expected to increase from 1 billion in 2020 to 1.4 billion. Overall, the aging population's desire for parenthood and the need for fertility solutions drive the growth of the global follicle stimulating hormone market.

Growing Adoption of Assisted Reproductive Technology is the Major Driver in the Global Follicle Stimulating Hormone Market

The use of assisted reproductive technology (ART) includes a variety of medical techniques designed to aid individuals in achieving pregnancy. In vitro fertilization (IVF) is one of the most well-known types of ART, in which eggs and sperm are mixed in a laboratory setting to fertilize and then implant the resulting embryos into the uterus.

Furthermore, the rising prevalence of polycystic ovary syndrome (PCOS) has contributed to an increase in infertility. PCOS is a common cause of female infertility, affecting roughly 6% to 12% of women of reproductive age in the United States, according to the Centers for Disease Control and Prevention (CDC) 2022 statistics. The continued prevalence of PCOS will drive demand for infertility treatments, consequently propelling the global follicle stimulating hormone market over the forecast period.

Significant Emotional and Psychological Toll on Individuals Due to Fertility Challenges and the Need for Assisted Reproductive Technologies Will Hamper the Growth of the Market.

The psychosocial consequences of infertility and ART are extensive, and they can have a significant impact on patients' sense of self-identity and personal agency, mental well-being, sexual and marital relationships, reproductive efficiency, treatment compliance, and pregnancy outcomes. Between 25% and 65% of women receiving ART experience clinical stress, anxiety, and negative emotions such as low self-esteem or guilt. Hence, the above mentioned factors are limiting the follicle stimulating hormone market's growth.

COVID-19 Impact Analysis

The financial health of companies across all industries has been impacted by the COVID-19 pandemic and lockdown in numerous nations throughout the world. Therefore, for the period of the COVID-19 public health emergency, the U.S. Food and Drug Administration (FDA) issued guidelines that include general considerations to aid sponsors and researchers, ensuring the safety of trial participants, adhering to good clinical practice (GCP), and minimizing risks to trial integrity.

Russia-Ukraine War Impact Analysis

The conflict between Russia and Ukraine has the potential to cause supply chain interruptions, uncertainty, and instability, which could affect the worldwide follicle-stimulating hormone (FSH) market. FSH product development and clinical trials would be impacted, which would slow down innovation. Market participants might look for FSH production diversification and alternate sources.

Furthermore, pricing and demand may be impacted by the economic impact, which includes currency fluctuations and modifications to market dynamics. There may be regional variances, with nations closer to the conflict feeling the effects more immediately. In order to navigate potential obstacles and seize possibilities in the FSH market, industry stakeholders must maintain constant observation and flexibility.

Segment Analysis

The global follicle stimulating hormone market is segmented based on type, application, end user, and region.

Recombinant FSH Segment Accounts for 56.3% of the Market Share Owing to Rising Demand for it.

Recombinant FSH products are produced in the laboratory and have various advantages over urinary-derived FSH products. One significant advantage is their superior purity, as they are free of contaminants commonly present in urinary-derived FSH. This provides consistent potency and reduces the possibility of contamination.

Gonal-f, Follistim, and Puregon are examples of rFSH medicines that have a sizable market share. Because of their effectiveness and high-quality standards, these brands have gained favor among healthcare providers and patients. They are trusted choices in reproductive treatments, including regulated ovarian stimulation in ART procedures such as IVF.

For instance, Bharat Serums and Vaccines Limited is conducting a clinical trial using Recombinant Human Follicle Stimulating Hormone for treating infertility. About 250 women in the age group of 20 to 39 years have participated in this trial and currently, it is in phase 3 trial and the estimated completion of the trial is in November 2023. Therefore, owing to the above reasons, the recombinant FSH segment is expected to drive the market growth over the forecast period.

Geographical Analysis

North America Accounted for Approximately 41.4% of the Market Share Owing to the Investment by the Major Players' Presence in this Region

North America's market dominance has been facilitated by the presence of established and influential companies, increased awareness and an increase in the rate of infertility growth which is related to unhealthy lifestyles and diets. Also, the rising healthcare costs and the widespread use of FSH products, along with an increase in inpatient visits to gynecologists are driving the market demand in North America.

Furthermore, Fertility Awareness Methods (FAMs), for example, are recognized by the United States Agency for International Development (USAID) as modern contraceptives that meet specified requirements, such as safety, effectiveness in preventing conception, and a basic grasp of reproductive biology.

FAMs have been evaluated in well-designed studies to determine their efficacy under a variety of situations. FAMs also have the advantage of not requiring clinical involvement and can be delivered through a variety of service delivery methods. As a result of the aforementioned factors, the North American region is expected to hold the biggest market share throughout the projection period.

Competitive Landscape

The major global players in the follicle stimulating hormone market include: Merck Serono, Creative BioMart, Midas Pharma GmbH, GenPharm, Trumac Healthcare, Livzon, Shanghai Techwell Biopharmaceutical Co., Ltd., Merck Sharp & Dohme Corp, Lee Biosolutions, Inc, and BIOGENIX INC.PVT.LTD.

Why Purchase the Report?

  • To visualize the global follicle stimulating hormone market segmentation based on type, application, end user and region and understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of Follicle stimulating hormone market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as Excel consisting of key products of all the major players.

The global follicle stimulating hormone market report would provide approximately 53 tables, 54 figures and 195 Pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Type
  • 3.2. Snippet by Application
  • 3.3. Snippet by End User
  • 3.4. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. An Increase in Aging Population
      • 4.1.1.2. Growing Adoption of Assisted Reproductive Technology
    • 4.1.2. Restraints
      • 4.1.2.1. Emotional and Psychological Toll on Individuals due to Fertility Challenges
    • 4.1.3. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's 5 Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Scenario Before COVID-19
    • 6.1.2. Scenario During COVID-19
    • 6.1.3. Scenario Post COVID-19
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 7.1.2. Market Attractiveness Index, By Type
  • 7.2. Recombinant FSH*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Urinary FSH

8. By Application

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.1.2. Market Attractiveness Index, By Application
  • 8.2. Infertility Treatment*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Assisted Reproductive Technology (ART)
  • 8.4. Others

9. By End User

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 9.1.2. Market Attractiveness Index, By End User
  • 9.2. Infertility Center*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Hospitals
  • 9.4. Others

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. The U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. The U.K.
      • 10.3.6.3. France
      • 10.3.6.4. Spain
      • 10.3.6.5. Italy
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia-Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan

Australia

      • 10.5.6.4. Rest of Asia-Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User

11. Competitive Landscape

  • 11.1. Competitive Scenario
  • 11.2. Market Positioning/Share Analysis
  • 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

  • 12.1. Merck Serono*
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Financial Overview
    • 12.1.4. Key Developments
  • 12.2. Creative BioMart
  • 12.3. Midas Pharma GmbH
  • 12.4. GenPharm
  • 12.5. Trumac Healthcare
  • 12.6. Livzon
  • 12.7. Shanghai Techwell Biopharmaceutical Co., Ltd.
  • 12.8. Merck Sharp & Dohme Corp
  • 12.9. Lee Biosolutions,Inc
  • 12.10. BIOGENIX INC.PVT.LTD.

LIST NOT EXHAUSTIVE

13. Appendix

  • 13.1. About Us and Services
  • 13.2. Contact Us